A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
UR001
Phase 1 other active
Quick answer
A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) for Non-muscle Invasive Bladder Cancer is a Phase 1 program (other) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lacuna Pharma Pty Ltd
- Indication
- Non-muscle Invasive Bladder Cancer
- Phase
- Phase 1
- Modality
- other
- Status
- active